Article
Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Molecular cancer therapeutics - 1 Apr 2003
Barnes Christopher J, Bagheri-Yarmand Rozita, Mandal Mahitosh, Yang Zhibo, Clayman Gary L, Hong Waun Ki, Kumar Rakesh
Abstract excerpt
Abnormalities in the expression and signaling pathways downstream of the epidermal growth factor receptor (EGFR) contribute to malignant transformation in human cancers, including those of the cutaneous epithelium. Accordingly, novel agents such as the EGFR tyrosine kinase inhibitor ZD1839 (Iressa), are promising, biologically based treatments that are currently in preclinical and clinical development. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.